Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech plans $160 million private stock sale at $92.50 per share

Mixed Impact 3 of 5 financing Written later

On May 21, 2023, Krystal Biotech agreed to sell 1,729,729 shares of common stock to institutional investors at $92.50 per share, for an aggregate purchase price of approximately $160 million before offering expenses. The company plans to use the proceeds for commercialization of VYJUVEK, its clinical pipeline, business development, and working capital, and expects the sale to close on May 22, 2023. The new shares add to the company's outstanding share count, which dilutes existing shareholders, while the company says the funds should support operations through the end of 2026.

Key points

  • 1,729,729 shares of common stock to be sold at $92.50 per share, for approximately $160 million in gross proceeds before offering-related expenses
  • Agreement dated May 21, 2023; closing expected May 22, 2023, subject to customary conditions
  • Financing led by Avoro Capital Advisors and Redmile Group, LLC, with participation from Braidwell LP and Frazier Life Sciences
  • Company agreed to file a registration statement for resale of the shares within 60 days of closing

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECMay 22, 2023, 7:32 AM ET
Accession number0001711279-23-000039

Items reported: 1.01 Material Definitive Agreement3.02 Unregistered Equity Sale7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on May 22, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.